Humanigen (KaloBios Pharmaceuticals) Priced, Nasdaq: HGEN
Developing monoclonal antibodies to treat respiratory diseases and cancer.
Industry: Health Care
First Day Return: 0.0%
Industry: Health Care
HGEN
Developing monoclonal antibodies to treat respiratory diseases and cancer.
| IPO Data | |
|---|---|
| IPO File Date | 10/05/2012 |
| Offer Price | $8.00 |
| Price Range $8.00 - $9.00 | |
| Offer Shares (mm) | 8.8 |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 01/30/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $70 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | South San Francisco, CA, United States |
| Founded | 2001 |
| Employees at IPO | 20 |
| Website www.kalobios.com | |
IPO News for Humanigen (KaloBios Pharmaceuticals)
Humanigen (KaloBios Pharmaceuticals) (HGEN) Performance
